結合型ワクチン市場：タイプ別、適応症別、病原体タイプ別、エンドユーザー別-2025-2030年の世界予測

結合型ワクチン市場の2023年の市場規模は396億7,000万米ドル、2024年には439億2,000万米ドルに達すると予測され、CAGR 10.81％で成長し、2030年には814億2,000万米ドルに達すると予測されます。

結合型ワクチンは、髄膜炎、肺炎、インフルエンザ菌b型（Hib）などの侵襲性疾患の予防に不可欠であり、多糖類抗原をタンパク質キャリアに結合させることで、特に幼児における免疫原性を高めています。その必要性は、長期間持続する免疫応答と群間免疫を生成し、疾病発生率を低下させる能力に由来します。主な用途としては、特定の感染症に罹患しやすい乳幼児、幼児、成人を対象とした予防接種プログラムが挙げられます。最終用途には、病院、診療所、公衆衛生機関、調査機関などが含まれます。主な成長要因としては、ワクチンで予防可能な病気に対する意識の高まり、政府の予防接種イニシアティブ、ワクチン開発における技術進歩などが挙げられます。市場は、ヘルスケア・インフラへの持続的な投資と、医療政策の厳格化による小児用ワクチンの需要増によって支えられています。COVID-19の大流行もワクチンの重要性を浮き彫りにし、予防ヘルスケアに対する市場全体の注目度を高めています。予防接種率が低い地域にも新たなビジネスチャンスがあり、市場拡大の可能性を浮き彫りにしています。研究開発分野での戦略的提携は技術革新を推進し、市場参入を最大化することができます。しかし、ワクチン開発へのためらい、サプライチェーンの混乱、ワクチン開発コストの高騰といった制約が成長を阻害する可能性があります。広範な臨床評価を必要とする厳しい規制状況は、さらなる課題となっています。革新は、耐熱性ワクチン、新規アジュバントシステム、複数の病原体に同時に対応する混合ワクチンの開発において発展する可能性があります。新たな結合機構や代替キャリアタンパク質を探索することで、有効性を高め、防護範囲を広げることができます。市場の競争は依然として激しく、ワクチンの入手可能性を拡大するために、バイオテクノロジー企業、国際保健機関、政府機関の間の提携が重視されています。ワクチン設計にAIや機械学習などの最先端技術を活用することで、企業はワクチンの効率を最適化し、新たな病原体の課題をターゲットにすることができ、この分野のリーダーとしての地位を確立することができます。

市場力学：急速に進化する結合型ワクチン市場の主要市場インサイトを公開

結合型ワクチン市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 感染症および免疫抑制の流行増加
  • がん治療用ワクチンの採用増加
  • WHOによるワクチン接種促進プログラムの増加
• 市場抑制要因
  • 遠隔地におけるワクチンへのアクセスの低さ
• 市場機会
  • 感染症に対する認識を広める政府の取り組み
  • 新規結合型ワクチン製造技術の進歩
• 市場の課題
  • 結合型ワクチンの製造手順の複雑さ

ポーターの5つの力：結合型ワクチン市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、結合型ワクチン市場の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することで、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：結合型ワクチン市場における外部からの影響の把握

外部マクロ環境要因は、結合型ワクチン市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析結合型ワクチン市場における競合情勢の把握

結合型ワクチン市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス結合型ワクチン市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、結合型ワクチン市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨結合型ワクチン市場における成功への道筋を描く

結合型ワクチン市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を検討することで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 感染症と免疫抑制の増加
    • がん治療ワクチンの採用増加
    • WHOによるワクチン接種促進プログラムの増加
  • 抑制要因
    • 遠隔地ではワクチンへのアクセスが低い
  • 機会
    • 感染症に関する意識を広める政府の取り組み
    • 新規結合ワクチン製造技術の進歩
  • 課題
    • 結合型ワクチンの制作手順の複雑さ
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 結合型ワクチン市場：タイプ別

• 一価
• 多価

第7章 結合型ワクチン市場適応症別

• ジフテリアと百日咳
• インフルエンザ
• 髄膜炎菌
• 肺炎球菌

第8章 結合型ワクチン市場病原体の種類別

• 細菌結合型ワクチン
• 組み合わせ結合型ワクチン
• バイラル結合型ワクチン

第9章 結合型ワクチン市場：エンドユーザー別

• 大人
• 子供たち

第10章 南北アメリカの結合型ワクチン市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域の結合型ワクチン市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの結合型ワクチン市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Bavarian Nordic
• Bharat Biotech Ltd.
• Bio-Med Limited
• Biological E. Limited
• Biological E. Ltd
• CSL Limited
• GlaxoSmithKline, plc.
• Merck and Company
• Novartis AG
• Nuron Biotech Inc.
• Pfizer, Inc.
• Sanofi Pasteur U.S., LLC
• Serum Institute of India Pvt. Ltd.
• Taj Pharmaceuticals Limited
• Vaxcyte, Inc.

LIST OF FIGURES

• FIGURE 1. CONJUGATE VACCINE MARKET RESEARCH PROCESS
• FIGURE 2. CONJUGATE VACCINE MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL CONJUGATE VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES CONJUGATE VACCINE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES CONJUGATE VACCINE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. CONJUGATE VACCINE MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. CONJUGATE VACCINE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. CONJUGATE VACCINE MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL CONJUGATE VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. CONJUGATE VACCINE MARKET DYNAMICS
• TABLE 7. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY MONOVALENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY MULTIVALENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY DIPHTHERIA & PERTUSSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY INFLUENZA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY MENINGOCOCCAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY PNEUMOCOCCAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY BACTERIAL CONJUGATE VACCINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY COMBINATION CONJUGATE VACCINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY VIRAL CONJUGATE VACCINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY CHILDREN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 27. ARGENTINA CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 28. ARGENTINA CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 29. ARGENTINA CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
• TABLE 30. ARGENTINA CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 31. BRAZIL CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 32. BRAZIL CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 33. BRAZIL CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
• TABLE 34. BRAZIL CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 35. CANADA CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 36. CANADA CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 37. CANADA CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
• TABLE 38. CANADA CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 39. MEXICO CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 40. MEXICO CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 41. MEXICO CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
• TABLE 42. MEXICO CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 43. UNITED STATES CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 44. UNITED STATES CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 45. UNITED STATES CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
• TABLE 46. UNITED STATES CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 47. UNITED STATES CONJUGATE VACCINE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 48. ASIA-PACIFIC CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 49. ASIA-PACIFIC CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 50. ASIA-PACIFIC CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
• TABLE 51. ASIA-PACIFIC CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 52. ASIA-PACIFIC CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 53. AUSTRALIA CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 54. AUSTRALIA CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 55. AUSTRALIA CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
• TABLE 56. AUSTRALIA CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 57. CHINA CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 58. CHINA CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 59. CHINA CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
• TABLE 60. CHINA CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 61. INDIA CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 62. INDIA CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 63. INDIA CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
• TABLE 64. INDIA CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 65. INDONESIA CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 66. INDONESIA CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 67. INDONESIA CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
• TABLE 68. INDONESIA CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 69. JAPAN CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 70. JAPAN CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 71. JAPAN CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
• TABLE 72. JAPAN CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 73. MALAYSIA CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 74. MALAYSIA CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 75. MALAYSIA CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
• TABLE 76. MALAYSIA CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 77. PHILIPPINES CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 78. PHILIPPINES CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 79. PHILIPPINES CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
• TABLE 80. PHILIPPINES CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 81. SINGAPORE CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 82. SINGAPORE CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 83. SINGAPORE CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
• TABLE 84. SINGAPORE CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 85. SOUTH KOREA CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 86. SOUTH KOREA CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 87. SOUTH KOREA CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
• TABLE 88. SOUTH KOREA CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 89. TAIWAN CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 90. TAIWAN CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 91. TAIWAN CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
• TABLE 92. TAIWAN CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 93. THAILAND CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 94. THAILAND CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 95. THAILAND CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
• TABLE 96. THAILAND CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 97. VIETNAM CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 98. VIETNAM CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 99. VIETNAM CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
• TABLE 100. VIETNAM CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 101. EUROPE, MIDDLE EAST & AFRICA CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 102. EUROPE, MIDDLE EAST & AFRICA CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 103. EUROPE, MIDDLE EAST & AFRICA CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
• TABLE 104. EUROPE, MIDDLE EAST & AFRICA CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 105. EUROPE, MIDDLE EAST & AFRICA CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 106. DENMARK CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 107. DENMARK CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 108. DENMARK CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
• TABLE 109. DENMARK CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 110. EGYPT CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 111. EGYPT CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 112. EGYPT CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
• TABLE 113. EGYPT CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 114. FINLAND CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 115. FINLAND CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 116. FINLAND CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
• TABLE 117. FINLAND CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 118. FRANCE CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 119. FRANCE CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 120. FRANCE CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
• TABLE 121. FRANCE CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 122. GERMANY CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 123. GERMANY CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 124. GERMANY CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
• TABLE 125. GERMANY CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 126. ISRAEL CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 127. ISRAEL CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 128. ISRAEL CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
• TABLE 129. ISRAEL CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 130. ITALY CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 131. ITALY CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 132. ITALY CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
• TABLE 133. ITALY CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 134. NETHERLANDS CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 135. NETHERLANDS CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 136. NETHERLANDS CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
• TABLE 137. NETHERLANDS CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 138. NIGERIA CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 139. NIGERIA CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 140. NIGERIA CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
• TABLE 141. NIGERIA CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 142. NORWAY CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 143. NORWAY CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 144. NORWAY CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
• TABLE 145. NORWAY CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 146. POLAND CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 147. POLAND CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 148. POLAND CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
• TABLE 149. POLAND CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 150. QATAR CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 151. QATAR CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 152. QATAR CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
• TABLE 153. QATAR CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 154. RUSSIA CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 155. RUSSIA CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 156. RUSSIA CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
• TABLE 157. RUSSIA CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 158. SAUDI ARABIA CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 159. SAUDI ARABIA CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 160. SAUDI ARABIA CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
• TABLE 161. SAUDI ARABIA CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 162. SOUTH AFRICA CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 163. SOUTH AFRICA CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 164. SOUTH AFRICA CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
• TABLE 165. SOUTH AFRICA CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 166. SPAIN CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 167. SPAIN CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 168. SPAIN CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
• TABLE 169. SPAIN CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 170. SWEDEN CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 171. SWEDEN CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 172. SWEDEN CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
• TABLE 173. SWEDEN CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 174. SWITZERLAND CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 175. SWITZERLAND CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 176. SWITZERLAND CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
• TABLE 177. SWITZERLAND CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 178. TURKEY CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 179. TURKEY CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 180. TURKEY CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
• TABLE 181. TURKEY CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 182. UNITED ARAB EMIRATES CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 183. UNITED ARAB EMIRATES CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 184. UNITED ARAB EMIRATES CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
• TABLE 185. UNITED ARAB EMIRATES CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 186. UNITED KINGDOM CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 187. UNITED KINGDOM CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 188. UNITED KINGDOM CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
• TABLE 189. UNITED KINGDOM CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 190. CONJUGATE VACCINE MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 191. CONJUGATE VACCINE MARKET, FPNV POSITIONING MATRIX, 2023

The Conjugate Vaccine Market was valued at USD 39.67 billion in 2023, expected to reach USD 43.92 billion in 2024, and is projected to grow at a CAGR of 10.81%, to USD 81.42 billion by 2030.

Conjugate vaccines are critical in preventing invasive diseases like meningitis, pneumonia, and Haemophilus influenzae type b (Hib) by linking polysaccharide antigens to protein carriers, enhancing immunogenicity, especially in young children. Their necessity stems from their ability to generate long-lasting immune responses and herd immunity, reducing disease incidence. Applications mainly include immunization programs targeting infants, young children, and adults with higher susceptibility to certain infectious diseases. End-use scope encompasses hospitals, clinics, public health agencies, and research institutions. Key growth influencers include heightened awareness of vaccine-preventable diseases, government immunization initiatives, and technological advancements in vaccine development. The market is buoyed by persistent investments in healthcare infrastructure and rising demand for pediatric vaccines due to stricter healthcare policies. The COVID-19 pandemic has also underscored the significance of vaccines, broadening the overall market focus on preventive healthcare. Emerging opportunities lie in geographical regions with low immunization coverage, highlighting the potential for expanding market footprints. Strategic collaborations in research and development sectors can propel technological innovations, maximizing market access. However, limitations such as vaccine hesitancy, supply chain disruptions, and high costs of vaccine development could impede growth. Stringent regulatory landscapes requiring extensive clinical evaluations pose additional challenges. Innovation can thrive in the development of thermostable vaccines, novel adjuvant systems, and combination vaccines that address multiple pathogens simultaneously. Exploring new mechanisms of conjugation and alternative carrier proteins can enhance efficacy and broaden protective scope. The nature of the conjugate vaccine market remains highly competitive, with a focus on partnerships between biotech firms, global health bodies, and governmental agencies to expand vaccine accessibility. By leveraging cutting-edge technologies like AI and machine learning in vaccine design, companies can optimize vaccine efficiency and target new pathogenic challenges, positioning themselves as leaders in the field.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Conjugate Vaccine Market

The Conjugate Vaccine Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing prevalence of infectious diseases and immunosuppression
  • Rising adoption of cancer therapeutic vaccines
  • Rising number programs to promote vaccination by WHO
• Market Restraints
  • Low accessibility to vaccines in remote areas
• Market Opportunities
  • Government initiatives spreading awareness about infectious diseases
  • Advancement in technology for producing novel conjugate vaccines
• Market Challenges
  • Complexity of production procedure of conjugate vaccine

Porter's Five Forces: A Strategic Tool for Navigating the Conjugate Vaccine Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Conjugate Vaccine Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Conjugate Vaccine Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Conjugate Vaccine Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Conjugate Vaccine Market

A detailed market share analysis in the Conjugate Vaccine Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Conjugate Vaccine Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Conjugate Vaccine Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Conjugate Vaccine Market

A strategic analysis of the Conjugate Vaccine Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Conjugate Vaccine Market, highlighting leading vendors and their innovative profiles. These include Bavarian Nordic, Bharat Biotech Ltd., Bio-Med Limited, Biological E. Limited, Biological E. Ltd, CSL Limited, GlaxoSmithKline, plc., Merck and Company, Novartis AG, Nuron Biotech Inc., Pfizer, Inc., Sanofi Pasteur U.S., LLC, Serum Institute of India Pvt. Ltd., Taj Pharmaceuticals Limited, and Vaxcyte, Inc..

Market Segmentation & Coverage

This research report categorizes the Conjugate Vaccine Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Monovalent and Multivalent.
• Based on Indication, market is studied across Diphtheria & Pertussis, Influenza, Meningococcal, and Pneumococcal.
• Based on Pathogen Type, market is studied across Bacterial Conjugate Vaccine, Combination Conjugate Vaccine, and Viral Conjugate Vaccine.
• Based on End-User, market is studied across Adults and Children.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of infectious diseases and immunosuppression
    • 5.1.1.2. Rising adoption of cancer therapeutic vaccines
    • 5.1.1.3. Rising number programs to promote vaccination by WHO
  • 5.1.2. Restraints
    • 5.1.2.1. Low accessibility to vaccines in remote areas
  • 5.1.3. Opportunities
    • 5.1.3.1. Government initiatives spreading awareness about infectious diseases
    • 5.1.3.2. Advancement in technology for producing novel conjugate vaccines
  • 5.1.4. Challenges
    • 5.1.4.1. Complexity of production procedure of conjugate vaccine
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Conjugate Vaccine Market, by Type

• 6.1. Introduction
• 6.2. Monovalent
• 6.3. Multivalent

7. Conjugate Vaccine Market, by Indication

• 7.1. Introduction
• 7.2. Diphtheria & Pertussis
• 7.3. Influenza
• 7.4. Meningococcal
• 7.5. Pneumococcal

8. Conjugate Vaccine Market, by Pathogen Type

• 8.1. Introduction
• 8.2. Bacterial Conjugate Vaccine
• 8.3. Combination Conjugate Vaccine
• 8.4. Viral Conjugate Vaccine

9. Conjugate Vaccine Market, by End-User

• 9.1. Introduction
• 9.2. Adults
• 9.3. Children

10. Americas Conjugate Vaccine Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Conjugate Vaccine Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Conjugate Vaccine Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Bavarian Nordic
• 2. Bharat Biotech Ltd.
• 3. Bio-Med Limited
• 4. Biological E. Limited
• 5. Biological E. Ltd
• 6. CSL Limited
• 7. GlaxoSmithKline, plc.
• 8. Merck and Company
• 9. Novartis AG
• 10. Nuron Biotech Inc.
• 11. Pfizer, Inc.
• 12. Sanofi Pasteur U.S., LLC
• 13. Serum Institute of India Pvt. Ltd.
• 14. Taj Pharmaceuticals Limited
• 15. Vaxcyte, Inc.